Drugs / SH3809
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04843033 | Apr 2021 → Oct 2023 | cancer or benign tumor | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH3809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04843033 ↗ |
| Action | Inhibit | “a small molecule inhibitor of SHP2 receptor” NCT04843033 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of SHP2 receptor” NCT04843033 ↗ |
| Route | Oral | “2mg,oral administered once daily” NCT04843033 ↗ |